jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

June. 29, 2021

Nov. 15, 2024

jRCT2031210172

ONO-7913-03:An open-label, uncontrolled study of ONO-7913 and ONO-4538 in combination with modified FOLFIRINOX as first-line treatment in patients with metastatic pancreatic cancer

ONO-7913-03: ONO-7913 Phase 1 Study

Hirashima Yoshinori

Ono Pharmaceutical Co.,LTD

3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

+81-120626190

clinical_trial@ono-pharma.com

Center Information Medical

Ono Pharmaceutical Co.,LTD

3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

+81-120626190

clinical_trial@ono-pharma.com

Not Recruiting

July. 01, 2021

July. 30, 2021
30

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1. Untreated metastatic pancreatic cancer
2. Life expectancy of at least 3 months
3. Patients with ECOG performance status 0 or 1

1. Patients with severe complication
2. Patients with multiple primary cancers

20age old over
No limit

Both

Untreated metastatic pancreatic cancer

Administration of ONO-7913 and ONO-4538 in combination with mFFX therapy

Tolerability, safety

Ono Pharmaceutical Co.,LTD
Kanagawa Cancer Center Research Ethics Review Board
2-3-2, Nakao, Asahi,Yokohama, Kanagawa

+81-45-520-2222

Approval

July. 12, 2021

No

NCT06532344

none

History of Changes

No Publication date
8 Nov. 15, 2024 (this page) Changes
7 Nov. 12, 2024 Detail Changes
6 Sept. 04, 2024 Detail Changes
5 Feb. 16, 2023 Detail Changes
4 Oct. 07, 2022 Detail Changes
3 Nov. 12, 2021 Detail Changes
2 Sept. 07, 2021 Detail Changes
1 June. 29, 2021 Detail